Inhibrx Biosciences, Inc. reports a Return on Equity (ROE) of 618.90%.

What is INBX's dividend yield?

Inhibrx Biosciences, Inc. offers a dividend yield of 0.00%.

What is INBX's Quality Score?

Our AI rates INBX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy INBX?

Our AI Timing Score for INBX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does INBX belong to?

Inhibrx Biosciences, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Inhibrx Biosciences, Inc. (INBX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

INBX AI Analysis Summary

Our AI summary for INBX: Inhibrx Biosciences, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 618.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

INBX

Inhibrx Biosciences, Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 83

USD 82.72

0.67 (0.82%) Day Change

Watchlist Portfolio Compare Chart

-8.43

D/E

618.9%

ROE

-70.8%

ROA

0.00%

Div Yield

INHIBRX BIOSCIENCES, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 82.72 Price 0.67 (0.82%) Day Change	NEWS SCORE: 83

INBX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	83
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	82.72
PBV / Sector	-57.23 / 44,219.29
Earning Per Share	-8.95

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	23.85 M GREAT
Average 1W Daily Value	13.57 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-10,014.23 / 98.22
NPM Average (%) / Sector	160,592.82 / -1,697.63 GREAT
NPM Change Average (%) / Sector	-1,599.66 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-70.77 / 185,260.96
ROA Average (%) / Sector	127.77 / 36,684.70 GREAT
ROA Change Average (%) / Sector	-342.53 / 422,221.66
ROE (%) / Sector	618.90 / 243,762.23 GREAT
ROE Average (%) / Sector	-135.00 / 48,758.47
ROE Change Average (%) / Sector	-144.98 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

41%

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	5.52 / 17.04 GREAT
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:41
Symbol	INBX
Name	INHIBRX BIOSCIENCES, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	14.67 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,203.77 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

Phone: 858 795 4220

Website: https://inhibrx.com

Employees: 109

Sector: Healthcare >> Biotechnology

Description: Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.